2. Recursion Pharmaceuticals (NASDAQ:RXRX)
Recursion Pharmaceuticals ranks No. 2 because it sits at the intersection of two major market themes: artificial intelligence and drug discovery. Trading around $3.59 with a market capitalization near $1.90 billion, RXRX is larger than many names on this list, but it still trades like a biotech penny stock and attracts attention from both healthcare investors and AI-focused traders.
The core story is simple but powerful. Recursion is trying to use artificial intelligence, automation, machine learning, and large biological datasets to change how drugs are discovered and developed. Traditional pharmaceutical research is slow, expensive, and filled with failure. The promise of AI drug discovery is that companies may be able to identify better targets, screen opportunities faster, and improve the odds of clinical success. That promise is why RXRX remains one of the most searched and watched AI biotech stocks on NASDAQ.
But the reason RXRX ranks this high is not just the story. It has financial breathing room. Recursion reported Q1 2026 updates showing reduced cash operating expense and about $665 million in cash, with runway into early 2028. In biotech, that matters tremendously. A company with a strong cash runway can keep developing programs without immediately pressuring shareholders through emergency financing. It can also negotiate partnerships from a stronger position.
The company also has multiple pipeline and partnered programs, which reduces the risk of being completely dependent on one single asset. That does not make RXRX safe, because clinical value still needs proof and revenue can be lumpy. But compared with many micro-cap biotech penny stocks, Recursion has a broader platform narrative and a more institutional-looking profile.
The risk is that the market eventually wants results, not just platform language. AI drug discovery is exciting, but investors will demand evidence that the platform can create clinically successful drugs. The stock can move on sentiment, partnerships, pipeline updates, or AI enthusiasm, but sustainable upside depends on proof.
Still, RXRX is one of the most compelling biotech penny stocks to watch this June because it gives investors exposure to healthcare innovation and artificial intelligence in one ticker. For SEO terms like “AI biotech stock,” “AI drug discovery penny stock,” “best biotech stocks under $5,” “NASDAQ healthcare stocks,” and “small-cap biotech stocks with cash runway,” Recursion is one of the strongest matches on the list. It is risky, but it has the kind of narrative and financial base that can keep investors interested.
Click next to see the following stock...
